NEW YORK (GenomeWeb News) – Coventry Health Care National Network has terminated its coverage agreement with Sequenom covering the MaterniT21 Plus test, just one week after the agreement was announced, the San Diego-based molecular diagnostics firm said after the close of the market on Thursday.

Coventry told Sequenom that the termination was without cause and was not a judgment on Sequenom, its Sequenom Center for Molecular Medicine subsidiary — which administers the non-invasive test for fetal aneuploidies — or its products, Sequenom said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.